ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

QGEN vs PCVX // EV/EBITDA & P/E VALUATION

Qiagen N.V. (NYSE) VS. Vaxcyte Inc. (NASDAQ) • 15-METRIC TALLY: QGEN 9 — PCVX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. PCVX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC QGEN PCVX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 62.20% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 8.00% -27.60% +35.60 QGEN /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 17.6x — — TIE /valuation <GO>
Free Cash Flow Yield 4.37% -6.79% +11.16 QGEN /fcf-yield <GO>
Operating Margin 22.30% -33.50% +55.80 QGEN /operating-margins <GO>
Net Profit Margin 20.30% 0.00% +20.30 QGEN /net-margins <GO>
Revenue Growth (YoY) 5.70% 19.80% -14.10 PCVX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.52% 0.00% +0.52 QGEN /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.54 18.11 -14.57 PCVX /balance-sheet <GO>
Piotroski F-Score Quality 9/9 4/9 +5.00 QGEN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 72.4 50.1 +22.30 QGEN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.95 1.07 -0.12 PCVX /macro-sensitivity <GO>
Forward P/E Multiple 22.7x 23.0x -0.30 QGEN /forward-pe <GO>
Enterprise Scale & Market Cap $10.37B $9.85B $519.6M QGEN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR QGEN REV PCVX REV QGEN GROSS % PCVX GROSS % QGEN FCF PCVX FCF
FY 2025 $2.09B $0 62.2% — $453.3M -$669.3M
FY 2024 $1.98B $0 48.9% — $506.4M -$475.1M
FY 2023 $1.97B $0 — — $371.0M -$296.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
PCVX // BETA 1.07